
Broad-Based Technical Strength Lifts Gland Pharma Ltd to 52-Week High of Rs 2296.9
2026-05-21 14:35:45Surging past its previous peaks, Gland Pharma Ltd touched a fresh 52-week high of Rs 2296.9 on 21 May 2026, marking a remarkable 45.5% gain over the past year. This rally stands in stark contrast to the broader Sensex, which has declined by 7.82% over the same period, underscoring the stock's strong momentum amid a challenging market backdrop.
Read More
Broad-Based Technical Strength Lifts Gland Pharma Ltd to 52-Week High of Rs 2295
2026-05-20 09:40:57With a decisive surge to Rs 2295 on 20 May 2026, Gland Pharma Ltd has reached a fresh 52-week high, marking a 50.32% gain over the past year. This rally stands in stark contrast to the Sensex’s 7.72% decline over the same period, underscoring the stock’s strong momentum amid a challenging broader market backdrop.
Read More
Broad-Based Technical Strength Lifts Gland Pharma Ltd to 52-Week High of Rs 2255
2026-05-19 09:41:10Surging to an intraday peak of Rs 2255 on 19 May 2026, Gland Pharma Ltd has marked a fresh 52-week high, extending its impressive rally that has delivered nearly 50% returns over the past year. This milestone comes amid a backdrop of strong technical momentum and a market environment where the broader Sensex trades cautiously below key moving averages.
Read More
Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-04-27 08:02:44Gland Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of late April 2026. Despite a recent downgrade in its Mojo Grade from Sell to Hold, the stock’s mixed technical indicators and price action suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.
Read More
Gland Pharma Ltd is Rated Hold
2026-04-21 10:10:33Gland Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-04-17 08:04:08Gland Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of April 2026. Despite a recent downgrade in technical trend, the stock’s fundamental performance and mixed indicator signals suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.
Read More
Gland Pharma Ltd is Rated Hold
2026-04-10 10:10:57Gland Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 March 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals and market performance.
Read More
Gland Pharma Ltd is Rated Hold
2026-03-30 10:10:31Gland Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 March 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreGland Pharma's Technical Turbulence: 3.71% Weekly Decline Amid Mixed Signals
2026-03-21 12:03:17Key Events This Week 16 Mar: Downgrade to Sell amid technical weakness and valuation concerns 17 Mar: Technical momentum shifts to mildly bearish with mixed signals 19 Mar: Upgrade to Hold following technical improvements 20 Mar: Bearish momentum returns with price decline of 4.11% Week OpenRs.1,627.75 Week Close<div ...
Read MoreAnnouncement under Regulation 30 (LODR)-Resignation of Director
16-Jun-2026 | Source : BSEPlease find enclosed the announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16-Jun-2026 | Source : BSESchedule of Investor Meet Intimation
Announcement under Regulation 30 (LODR)-Change in Directorate
15-Jun-2026 | Source : BSEChanges among Board of Directors of the Company
Corporate Actions
No Upcoming Board Meetings
Gland Pharma Ltd has declared 1800% dividend, ex-date: 14 Aug 25
No Splits history available
No Bonus history available
No Rights history available